A new approach to protein degradation
Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.
Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.
CEO Nicola Thompson